Volume Spike Investor

Jazz Pharmaceuticals Inc. (Nasdaq: JAZZ) shares are up more than 30% on strong premarket volume and may be one of the most active biotech stocks today after the fibromyalgia treatment developer said preliminary data from a second Phase III trial of its pain drug Xyrem met its primary endpoint.

The company in a press release said 573 patients treated with Xyrem in a 14-week trial showed a 30% reduction in pain and fatigue and demonstrated improved daily function.

At least one other biotech’s stock may be affected by the news, due to a perceived competitive threat. – Mike Tarsala

Go to BioHealthInvestor.com for details